2.00
-0.19(-8.68%)
Currency In USD
| Previous Close | 2.19 |
| Open | 2.16 |
| Day High | 2.17 |
| Day Low | 2 |
| 52-Week High | 12.51 |
| 52-Week Low | 1.64 |
| Volume | 24.36M |
| Average Volume | 12.36M |
| Market Cap | 723.71M |
| PE | -1.65 |
| EPS | -1.21 |
| Moving Average 50 Days | 2.26 |
| Moving Average 200 Days | 3.06 |
| Change | -0.19 |
If you invested $1000 in Iovance Biotherapeutics, Inc. (IOVA) 10 years ago, it would be worth $309.12 as of October 30, 2025 at a share price of $2. Whereas If you bought $1000 worth of Iovance Biotherapeutics, Inc. (IOVA) shares 5 years ago, it would be worth $56.05 as of October 30, 2025 at a share price of $2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
GlobeNewswire Inc.
Oct 23, 2025 8:05 PM GMT
SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient
Iovance Biotherapeutics to Present at Upcoming Conferences
GlobeNewswire Inc.
Aug 29, 2025 12:30 PM GMT
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
GlobeNewswire Inc.
Aug 18, 2025 8:15 PM GMT
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA